CD34 and non-small cell lung carcinoma: Some studies have found that antiangiogenic therapy, such as chemotherapy plus bevacizumab [22]or anlotinib alone [29], is more effective in patients with more undifferentiated (CD31+/CD34-) MVD in advanced NSCLC.